Steven King | President and Chief Executive Officer
Mosaic Immunoengineering

Steven King, President and Chief Executive Officer, Mosaic Immunoengineering

Mr. King has more than 15 years as CEO and BOD member of NASDAQ biotechnology company Peregrine Pharmaceuticals. He helped raise over $250M to advance the company's lead product and grow their CDMO business.  Steve led the Peregrine team to advance the lead product from discovery through phase 3 clinical trials while growing CDMO revenues from startup to over $55M


Day 3 - November 30 @ 13:45

Development of CPMV-based vaccines against cancer

last published: 02/Jan/24 12:15 GMT

back to speakers